Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | PHASE1 | COMPLETED | 78 | — | — | May 29, 2019 | Feb 16, 2023 | Mar 30, 2023 | 28 | United States |
Rates of treatment-related adverse events (AEs), graded by CTCAE v4.03, and additionally categorized as either immune-related or non-immune AEs.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Arm 1: XmAb®22841 Monotherapy |
| Arm 2 | EXPERIMENTAL | Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®) |
| Name | Type | Description |
|---|---|---|
| XmAb®22841 | BIOLOGICAL | Monoclonal bispecific antibody |
| Pembrolizumab (Keytruda®) | BIOLOGICAL | FDA-approved humanized monoclonal antibody |
Inclusion Criteria: PART A (Dose Escalation Cohorts) 1. All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. 2. All subjects must have adequate archival tumor,...